Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
Abstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune‐associated medicine on PD‐1 (+) cells. Gene expressio...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166636161138688 |
|---|---|
| author | Wei Zhang Haorui Shen Yan Zhang Wei Wang Shaoxuan Hu Dongmei Zou Daobin Zhou |
| author_facet | Wei Zhang Haorui Shen Yan Zhang Wei Wang Shaoxuan Hu Dongmei Zou Daobin Zhou |
| author_sort | Wei Zhang |
| collection | DOAJ |
| description | Abstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune‐associated medicine on PD‐1 (+) cells. Gene expression profiling (GEP) was performed on circulating PD‐1 (+) cells from 22 PTCL patients and 13 healthy subjects, and circulating PD‐1 (−) cells from 2 PTCL patients. PD‐1 (+) cells were treated with chidamide, and the production IFN‐γ and cytotoxicity were analyzed. GEP were performed on circulating PD‐1 (+) cells from 2 PTCL patients treated with chidamide combined with chemotherapy and 1 patient treated with traditional chemotherapy. GEP showed that genes associated with innate immune response were abnormally expressed in PD‐1 (+) cells of PTCL patients compared with healthy subjects, meanwhile the expression of CTLA‐4 was significantly higher in PD‐1 (+) cells than that of PD‐1 (−) cells. In vitro study revealed decreased level of IFN‐γ secretion and impaired cytotoxic activity of PD‐1 (+) cells compared with PD‐1 (−) cells, while chidamide could recover the deficiencies and upregulate adaptive immune‐associated genes in PD‐1 (+) cells of PTCL patients. Our research indicated that PD‐1 (+) cells might have deficiencies in innate and adaptive immune response and chidamide may reverse the defects. |
| format | Article |
| id | doaj-art-d049a907c8c24782a93669ccf70a8558 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-d049a907c8c24782a93669ccf70a85582024-11-15T13:01:04ZengWileyCancer Medicine2045-76342019-05-01852104211310.1002/cam4.2097Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cellsWei Zhang0Haorui Shen1Yan Zhang2Wei Wang3Shaoxuan Hu4Dongmei Zou5Daobin Zhou6Department of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaDepartment of Hematology Peking Union Medical College Hospital Beijing P.R. ChinaAbstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune‐associated medicine on PD‐1 (+) cells. Gene expression profiling (GEP) was performed on circulating PD‐1 (+) cells from 22 PTCL patients and 13 healthy subjects, and circulating PD‐1 (−) cells from 2 PTCL patients. PD‐1 (+) cells were treated with chidamide, and the production IFN‐γ and cytotoxicity were analyzed. GEP were performed on circulating PD‐1 (+) cells from 2 PTCL patients treated with chidamide combined with chemotherapy and 1 patient treated with traditional chemotherapy. GEP showed that genes associated with innate immune response were abnormally expressed in PD‐1 (+) cells of PTCL patients compared with healthy subjects, meanwhile the expression of CTLA‐4 was significantly higher in PD‐1 (+) cells than that of PD‐1 (−) cells. In vitro study revealed decreased level of IFN‐γ secretion and impaired cytotoxic activity of PD‐1 (+) cells compared with PD‐1 (−) cells, while chidamide could recover the deficiencies and upregulate adaptive immune‐associated genes in PD‐1 (+) cells of PTCL patients. Our research indicated that PD‐1 (+) cells might have deficiencies in innate and adaptive immune response and chidamide may reverse the defects.https://doi.org/10.1002/cam4.2097adaptive immunechidamideinnate immuneperipheral T‐cell lymphomaprogrammed cell death‐1 |
| spellingShingle | Wei Zhang Haorui Shen Yan Zhang Wei Wang Shaoxuan Hu Dongmei Zou Daobin Zhou Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells Cancer Medicine adaptive immune chidamide innate immune peripheral T‐cell lymphoma programmed cell death‐1 |
| title | Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells |
| title_full | Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells |
| title_fullStr | Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells |
| title_full_unstemmed | Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells |
| title_short | Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells |
| title_sort | circulating pd 1 cells may participate in immune evasion in peripheral t cell lymphoma and chidamide enhance antitumor activity of pd 1 cells |
| topic | adaptive immune chidamide innate immune peripheral T‐cell lymphoma programmed cell death‐1 |
| url | https://doi.org/10.1002/cam4.2097 |
| work_keys_str_mv | AT weizhang circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT haoruishen circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT yanzhang circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT weiwang circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT shaoxuanhu circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT dongmeizou circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells AT daobinzhou circulatingpd1cellsmayparticipateinimmuneevasioninperipheraltcelllymphomaandchidamideenhanceantitumoractivityofpd1cells |